CHARLESTOWN, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will participate in the following three upcoming investor conferences:
A live webcast of the presentations will be available on the Events page of the Investors section of the Company website, or by clicking here. A webcast replay will be archived for 30 days on the Events page.
Institutional investors interested in meeting with management during the conference may reach out to their Jefferies, Cantor, or Chardan representatives.
About Solid Biosciences
Solid Biosciences is a life science company focused on advancing a portfolio of neuromuscular and cardiac programs, including SGT-003, a differentiated gene therapy candidate for the treatment of Duchenne muscular dystrophy (Duchenne), AVB-401, a gene therapy program for the treatment of BAG3 mediated dilated cardiomyopathy, AVB-202-TT, a gene therapy program for the treatment of Friedreich’s Ataxia, and additional assets for the treatment of fatal cardiac diseases. Solid aims to be the center of excellence across a given disease spectrum bringing together those with expertise in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Leah Monteiro
VP, Investor Relations & Communications
617-821-4427
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$4.85 |
| Daily Change: | -0.46 -8.66 |
| Daily Volume: | 350,011 |
| Market Cap: | US$187.210M |
November 06, 2024 August 13, 2024 May 07, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
